Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rezpegaldesleukin by Nektar Therapeutics for Alopecia Areata: Likelihood of Approval
Rezpegaldesleukin is under clinical development by Nektar Therapeutics and currently in Phase II for Alopecia Areata. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
NKTR-255 by Nektar Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
NKTR-255 by Nektar Therapeutics for Colon Carcinoma: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Colon Carcinoma. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Anal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cervical Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
NKTR-255 by Nektar Therapeutics for Solid Tumor: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Nektar Therapeutics gets grant for cancer treatment using 4-1bb and il-2rß agonists
Nektar Therapeutics has been granted a patent for a method of cancer treatment involving the administration of a 4-1BB agonist...
NKTR-255 by Nektar Therapeutics for Colon Carcinoma: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Colon Carcinoma. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Anal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cervical Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
NKTR-255 by Nektar Therapeutics for Solid Tumor: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Rezpegaldesleukin by Nektar Therapeutics for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Rezpegaldesleukin is under clinical development by Nektar Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to...
Nektar Therapeutics gets grant for long-acting il-15 receptor agonist for immune activation
Nektar Therapeutics has been granted a patent for a long-acting interleukin-15 (IL-15) receptor agonist. The composition includes poly(ethylene glycol)-interleukin-15 moiety...
Nektar Therapeutics gets grant for mixed-acid salt of water-soluble polymer-drug conjugate
Nektar Therapeutics has been granted a patent for a mixed-acid salt of a water-soluble polymer-drug conjugate, offering improved stability and...
Nektar Therapeutics files patent for polymer conjugates of TLR 7/8 agonists for cancer treatment
Nektar Therapeutics has filed a patent for multi-arm polymer conjugates of Toll-Like Receptor agonists, specifically TLR 7/8 agonists, for use...
Nektar Therapeutics gets grant for conjugate of tlr 7/8 agonist with water-soluble polymer
Nektar Therapeutics has been granted a patent for multi-arm polymer conjugates of Toll-Like Receptor (TLR) agonists, specifically TLR 7/8 agonists....
Nektar Therapeutics files patent for conjugate of water-soluble polymer and factor viii for administration
Nektar Therapeutics has filed a patent for conjugates that involve attaching a water-soluble polymer to a Factor VIII moiety through...